Drug Patent Watch
JUNE 25, 2024
DrugChatter is an innovative AI-powered search and answer engine designed to revolutionize how we access and comprehend information. Harnessing the power of advanced natural language processing, DrugChatter provides concise, accurate, and contextually relevant answers to a wide array of questions, making information retrieval faster and more intuitive than ever before.
Pharmaceutical Technology
JUNE 25, 2024
Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 25, 2024
The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.
Pharmaceutical Technology
JUNE 25, 2024
Novo Nordisk has unveiled a significant investment plan, committing $4.1bn to construct a second fill and finishing facility in Clayton.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 25, 2024
A woman in Colombia with rare genetic resistance to Alzheimer’s disease may have more company than scientists thought.
Pharmaceutical Technology
JUNE 25, 2024
Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
JUNE 25, 2024
The company plans to make a case to regulators for a new accelerated approval pathway. But investors didn't seem as hopeful, sending shares down by double digits.
Pharmaceutical Technology
JUNE 25, 2024
ETH47 is a type III interferon-encoding mRNA drug that could be used to treat respiratory diseases including uncontrolled asthma.
Bio Pharma Dive
JUNE 25, 2024
The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.
Pharmaceutical Technology
JUNE 25, 2024
Explore the critical aspects of pharma packaging solutions, design, and companies. What to look for to ensure product safety and compliance.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
JUNE 25, 2024
Atherosclerotic plaques in the arteries affect 42% of adults living without heart disease
Pharmaceutical Technology
JUNE 25, 2024
Discover the critical factors in choosing medical packaging companies for pharmaceutical contract manufacturing. Ensure quality with our guide.
pharmaphorum
JUNE 25, 2024
Discover practical use cases and common concerns surrounding the implementation of generative AI (GenAI) in clinical trials. Learn how this technology is transforming the landscape of medical research.
Pharmaceutical Technology
JUNE 25, 2024
Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.
Pharma Times
JUNE 25, 2024
An estimated 27% of patients globally living with diabetes will be affected by retinopathy
Pharmaceutical Technology
JUNE 25, 2024
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
pharmaphorum
JUNE 25, 2024
Explore the complexities of patient support in the realm of cell and gene therapies. Learn about the challenges and strategies for providing effective patient assistance in this cutting-edge field.
Pharmaceutical Technology
JUNE 25, 2024
At the Outsourcing in Clinical Trials UK and Ireland Conference, prominent figures in UK healthcare highlighted areas for change.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
XTalks
JUNE 25, 2024
The demand for food and beverage products with less sugar is rapidly increasing. Consumers are becoming more health-conscious, driven by a desire to avoid the negative health impacts associated with high sugar consumption, such as obesity and diabetes. As a result, food manufacturers are under pressure to find effective sugar reduction solutions to meet this demand.
pharmaphorum
JUNE 25, 2024
Discover how improving digital connectivity can enhance health services in the UK, with a focus on the NHS. Learn about the benefits of embracing digital technology for better healthcare outcomes.
Pharmaceutical Commerce
JUNE 25, 2024
The latest news for pharma industry insiders.
pharmaphorum
JUNE 25, 2024
A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign up for clinical trials.
BioPharma Reporter
JUNE 25, 2024
Last week, OSP had the pleasure of speaking with Ginny Beakes-Read at the DIA Global conference.
pharmaphorum
JUNE 25, 2024
Almost half of young adults who participated in a UK survey said they had made a health decision they regret based on misinformation
BioPharma Reporter
JUNE 25, 2024
Once monthly treatment with Novo Nordiskâs antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.
pharmaphorum
JUNE 25, 2024
Oral ketamine from Douglas Pharma shows efficacy in phase 2 treatment-resistant depression trial and will move into pivotal trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Patent Watch
JUNE 25, 2024
Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity trends in the pharmaceutical industry. The report, titled “USPTO Drug Patent and Exclusivity Study Report,” provides valuable insights into the patent landscape, patent duration, and exclusivity trends that shape the pharmaceutical industry.
pharmaphorum
JUNE 25, 2024
AstraZeneca’s hopes of positioning Imfinzi as a post-surgery therapy for people with early-stage NSCLC have taken a knock
Fierce Pharma
JUNE 25, 2024
A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established fo | A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa.
pharmaphorum
JUNE 25, 2024
Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned after failing a phase 3 trial.The TrilynX study was testing xevinapant with chemoradiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), but according to an interim look at the data was unlikely to meet its goal of extending event-free survival.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
105 
Let's personalize your content